Solid Tumors: Dose Escalation Only (Disease- Specific Expansion)	Advanced metastatic or recurrent tumors with BRCA mutation	Expansion: Ovarian Cancer, Metastatic Breast Cancer or Metastatic Castrate-Resistant Prostate Cancer	10551 : Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in BRCA Mutant Patients with Metastatic or Recurrent Solid Tumors
	Advanced solid tumors with positive HER2 expression	Expansion: metastatic gastric or GEJ cancer with HER2 expression by IHC (1+, 2+, or 3+) or HER2 amplification	*▼10554: Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression ((Limited: dose escalation; ETCTN-wide: expansion phase)
		Expansion: advanced/metastatic gastroesophageal cancer or colorectal cancer with positive HER2 expression	10358: Phase 1/1B Study of DS8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
		Expansion: HER2 positive uterine serous carcinoma	10355: A phase I study of DS-8201a in combination with olaparib in HER2-expressing malignancies
		Phase 2: advanced cholangiocarcinoma/ gallbladder carcinoma	10276: A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (Limited: Phase 1; ETCTN-wide: Phase 2)
		Expansion: NUT Carcinoma	10509 : A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors
		Expansion: Metastatic colorectal cancer	▼ 10579 : Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors